Data Collection

• Sources: Clinical trial registries (e.g., ClinicalTrials.gov), scientific publications, industry reports, and company disclosures.

• Inclusion Criteria: Trials focusing on specific therapeutic areas (e.g., oncology, cardiology) and MoAs (e.g., enzyme inhibitors, monoclonal antibodies).

Phase-wise Breakdown

• Phase I: Initial safety and dosage trials in healthy volunteers or patients.

• Phase II: Efficacy and side effect evaluation in a larger patient group.

• Phase III: Confirmation of efficacy, monitoring of side effects, and comparison with standard treatments in large patient groups.

• Phase IV: Post-marketing studies to delineate additional information including the drug’s risks, benefits, and optimal use.

Outcome Measures

• Success Rates: Percentage of trials that successfully progress to the next phase.

• Failure Rates: Trials that do not meet endpoints or are terminated.

• Adverse Events: Frequency and severity of reported side effects.

• Endpoints Achievement: Success in meeting primary and secondary clinical endpoints.

Analytical Tools

• Statistical Analysis: Utilization of statistical software to analyze data trends and correlations.

• Predictive Modeling: Machine learning models to predict trial outcomes based on historical data.

• Data Visualization: Graphs and charts to visually represent data for easier interpretation.